GTS Securities’s SAB Biotherapeutics Warrant SABSW Stock Holding History

GTS Securities’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.07K	Sell	41,001 -100	-0.2%	-$3	﹤0.01%	1468
2025 Q4	$1.03K	Buy	+41,101	New	+$1.25K	﹤0.01%	1346

Other funds holding SABSW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

GTS Securities's SABSW Position: Q1 2026 in Review

GTS Securities reduced its SAB Biotherapeutics Warrant (SABSW) stake by 0.24% in Q1 2026, selling an estimated $3 and leaving 41,001 shares worth $1.07K. The position accounts for ﹤0.01% of the portfolio, ranked #1468.

GTS Securities first reported a position in SABSW in Q4 2025 and has held it in 2 quarters since. 6 funds tracked by Wall St. Rank hold SABSW as of Q1 2026.

GTS Securities held 41,001 shares of SAB Biotherapeutics Warrant worth $1.07K as of Q1 2026.
GTS Securities sold 100 SAB Biotherapeutics Warrant shares in Q1 2026, an estimated $3.
SAB Biotherapeutics Warrant made up ﹤0.01% of GTS Securities's portfolio in Q1 2026, its #1468 holding.
GTS Securities first reported a position in SAB Biotherapeutics Warrant in Q4 2025 and has held it in 2 quarters since.
6 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.